A machine learning tool incorporating both clinical and genomic data helps predict response to CDK4/6 inhibitor therapy in ...

Drs Kathy Miller and Francisco J. Esteva discuss testing and therapeutic options for the new classification of HER2-ultra-low breast cancer.

Compared with originator bevacizumab, the biosimilar version of bevacizumab had equal efficacy when used to treat metastatic ...

Fred Hutch graduate student Adam Nguyen has won a F31 training award from the NIH to study a complex molecule called Tie2 ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

We’ve issued final draft guidance recommending a new once-a-day tablet that is set to benefit around 1,100 people with a type ...

Xcovery Holdings, Inc., an oncology focused pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for the ...

The Food and Drug Administration has approved Ensacove for patients with ALK-positive locally advanced or metastatic ...

Ensartinib has received FDA approval for the first-line treatment of ALK-positive locally advanced or metastatic non–small ...

A new once-a-day tablet that treats advanced breast cancer is to be rolled out on the NHS, with about 1,100 patients in ...

Ensartinib has received FDA approval for the first-line treatment of anaplastic lymphoma kinase (ALK)-positive locally ...